Sitagliptin enhances incretin hormone activity (GLP-1 and GIP), increasing insulin release and decreasing glucagon levels in a glucose-dependent manner.

Sitagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

100 mg orally once daily (with or without food).

Most common (≥5%):

• Upper respiratory tract infection
• Nasopharyngitis
• Headache

Hypoglycemia:

• Higher risk when used with insulin or sulfonylureas.

Known serious hypersensitivity to sitagliptin (e.g., anaphylaxis, angioedema).

Pancreatitis: Discontinue if suspected.

Heart Failure: Risk observed with DPP-4 inhibitors.

Renal Failure: Monitor kidney function before and during treatment.

Hypoglycemia: Increased risk when combined with insulin/sulfonylureas.

Hypersensitivity Reactions: Includes Stevens-Johnson syndrome.

Severe Arthralgia: Can occur at any time during therapy.

Bullous Pemphigoid: Discontinue if blistering occurs.